Physician profile
Michael D Chafty
NPI 1245205111
$1,946.50
in general payments reported to CMS, 2019-2025
23 companies · $58.65 in 2025
The $58.65 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $212 · 2021: $348 · 2022: $411 · 2023: $387 · 2024: $159 · 2025: $58.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $603.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $335.24 | 2019-2025 | Octrode |
| Collegium Pharmaceutical, INC. | $256.90 | 2021-2025 | Belbuca |
| Abbvie INC. | $216.49 | 2022-2025 | Ubrelvy, Qulipta |
| Nevro Corp. | $127.94 | 2019-2023 | Senza |
| Amgen INC. | $125.41 | 2019-2022 | |
| Medtronic USA, INC. | $110.96 | 2019-2020 | |
| Ibsa Pharma INC. | $99.89 | 2021-2023 | Tirosint, Licart |
| Pfizer INC. | $92.95 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $72.73 | 2022 | |
| Medtronic, INC. | $70.03 | 2021-2022 | |
| Lilly USA, LLC | $64.24 | 2023 | Reyvow, Emgality |
| Biodelivery Sciences International, INC. | $61.12 | 2020-2021 | |
| Boston Scientific Corporation | $61.00 | 2020-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.48 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $40.00 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $34.88 | 2019 | |
| Assertio Therapeutics, INC. | $34.06 | 2019 | |
| Horizon Therapeutics Plc | $22.88 | 2019 | |
| Redhill Biopharma INC. | $16.07 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.54 | 2019 | |
| Pacira Therapeutics, INC. | $15.39 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.74 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chafty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.